In Canada, 25,500 men will be diagnosed with prostate cancer in 2011, and 4,100 will die of the disease. New approaches are required to predict clinical outcome and personalized management of patients. Drs. Mai and Cayre will combine their two newly developed technologies and work towards obtaining a new solid biomarker that enables the assessment of a patient’s clinical outcome from the start. With the use of special filters, circulating tumour cells (CTC) will be isolated from prostate cancer patients’ blood.